Recent Updates
Recently added Catalysts
LTRN Positive Sentiment

Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone

Tuesday, November 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Lantern Pharma published Phase 1a data for LP-184 in recurrent glioblastoma patients. The results support a Phase 1b/2a combination trial with spironolactone. The findings appeared in Cancer Research Communications. This publication advances the development of LP-184 for central nervous system cancers.

Market Sentiment Analysis

POSITIVE FACTORS

  • Publication of Phase 1a data for LP-184
  • Supports upcoming Phase 1b/2a trial
  • Focus on recurrent glioblastoma treatment
  • Collaboration with Starlight Therapeutics

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+20%
120-day peak, hindsight
Typical move
4%
average across 5 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
LP-300
Phase 2 · Adenocarcinoma of Lung

Full Press Release Details

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, and its wholly owned subsidiary Starlight Therapeutics today announced the publication of Phase 1a clinical data for LP-184 (zirdafulven) in patients with recurrent GBM. LP-184 is being developed as STAR-001 for central nervous system (CNS) cancers. The paper appears in the October 2026 issue of Cancer Research Communications, a peer-reviewed journal of the American Association fo

Frequently Asked Questions

What is LP-184?

LP-184, or zirdafulven, targets CNS cancers like glioblastoma.

What does the data support?

It supports a Phase 1b/2a trial with spironolactone.

Where was the data published?

It appeared in Cancer Research Communications, October 2026.

What cancer does it target?

The drug targets recurrent glioblastoma in patients.

ShareAdd on Google
Tags: LTRN Lantern Pharma LP-184 recurrent glioblastoma CNS cancers Phase 1b/2a trial
Last updated: Nov 10, 2026

Biotech snapshot

Cash runway
$7M liquidity · $1M/mo burn
~5 mo
High dilution risk
Lead asset
LP-300Phase 2
Adenocarcinoma of Lung →

Catalyst track record

+20%
best trade around LTRN's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for LTRN.

See every catalyst's timing & PoA →